The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio
| Autor: | C Karkantaris, Meletios A. Dimopoulos, E Voskaridou, Amin Rahemtulla, Evangelos Terpos, Konstantinos Zervas, Marianna Politou, D Mihou, Richard Szydlo, K Tsimirika |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
musculoskeletal diseases
Adult Male Cancer Research medicine.medical_specialty medicine.drug_class Sialoglycoproteins Urology Receptors Cytoplasmic and Nuclear Ligands Dexamethasone Receptors Tumor Necrosis Factor Bone remodeling Osteoprotegerin Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Multiple myeloma Aged Glycoproteins Hematology Dose-Response Relationship Drug business.industry Middle Aged medicine.disease Survival Analysis Thalidomide Endocrinology Oncology Corticosteroid Female Osteopontin Bone Remodeling business Multiple Myeloma Biomarkers medicine.drug |
| Zdroj: | Leukemia. 19(11) |
| ISSN: | 0887-6924 |
| Popis: | The aim of this study was the evaluation of the effect of intermediate doses of thalidomide with dexamethasone (Thal/Dex) on disease course and bone disease in patients with refractory/relapsed myeloma who were under zoledronic acid therapy. We studied 35 patients, who received thalidomide at a dose of 200 mg/daily. We measured, pre-, 3 and 6 months post-treatment soluble receptor activator of nuclear factor-kappaB ligand (sRANKL), osteoprotegerin (OPG), osteopontin (OPN), markers of bone resorption and formation. Before treatment, patients had increased levels of sRANKL/OPG ratio, bone resorption markers and OPN, while they had suppressed bone formation. The pretreatment sRANKL/OPG ratio correlated with the extent of bone disease. Thal/Dex administration resulted in a significant reduction of sRANKL/OPG ratio, and bone resorption. Bone formation, OPG and OPN did not show any alteration. Changes of sRANKL/OPG ratio correlated with changes of bone resorption markers. Thal/Dex was given for a median time of 10 months and the median follow-up period was 22 months. The response rate was 65.7%. The median survival was 19.5 months. beta2-microglobulin, type of response and International Staging System predicted for survival. These results suggest that the combination of intermediate dose of Thal/Dex is effective in patients with refractory/relapsed myeloma and improves abnormal bone remodeling through the reduction of sRANKL/OPG ratio. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|